IRD NASDAQ
Credit Risk of going bust: higher than 70% of companies Debt: 11.2% of company value Bonds: none of note held by US funds details ▾
If the stock fell to about $0.06 (down 98%), Opus Genetics, Inc. would be worth roughly what it owes.
Total debt $34.9M against a stock market value of $276.2M.
Distance to default 3.44 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $17.5M (short-term plus half of long-term), stock volatility 79.6%; Altman Z'' -10.91. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Durham, NC 27713
US
Opus Genetics, Inc. is a clinical-stage biopharmaceutical company focused on ophthalmology. The company is dedicated to discovering and commercializing innovative therapies to address significant unmet medical needs in patients suffering from refractive and retinal eye disorders. Its portfolio includes Phentolamine Ophthalmic Solution, currently used to reverse pharmacologically induced mydriasis (pupil dilation). This solution is also advancing through Phase III clinical trials for the treatment of presbyopia and impaired vision in dim light or at night. A leading candidate in its retinal pipeline is APX3330, a small-molecule inhibitor targeting the reduction oxidation effector factor-1 protein. APX3330 has successfully completed Phase II clinical trials for diabetic retinopathy. Furthermore, Opus Genetics is developing APX2009 and APX2014, two preclinical product candidates also aimed at various retinal indications. Originally founded in 2018 as Ocuphire Pharma, Inc., the company maintains its headquarters in Farmington Hills, Michigan.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Magrath George | S-Sale | 9,591 | $3.58 | 2026-10-23 |
| Gagnon Robert E. | S-Sale | 14,000 | $3.55 | 2026-10-23 |
| SCHACHLE JOSEPH K | S-Sale | 4,767 | $3.56 | 2026-10-23 |
| YERXA BENJAMIN R | S-Sale | 7,669 | $3.55 | 2026-10-23 |
| YERXA BENJAMIN R | S-Sale | 25,520 | $3.53 | 2026-10-23 |